Clinical Trial Update: Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma [Phase 1]

View source ↗

Summary

Phase 1 study of chlorotoxin-targeted CAR T cells targeting MMP2 in patients with recurrent glioblastoma and other recurrent gliomas. The trial is currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma
• Malignant Glioma

Drugs mentioned

• Chlorotoxin-targeted CAR T cells for MMP2+ glioblastoma

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Glioblastoma, Recurrent Malignant Glioma | Phase 1 | Status: ACTIVE_NOT_RECRUITING